Michael Gensheimer (@mfgensheimer) 's Twitter Profile
Michael Gensheimer

@mfgensheimer

Radiation oncologist at @StanfordRadOnc. Research in predictive modeling and imaging. Creator of nnet-survival for survival modeling with neural networks.

ID: 712320951942184960

linkhttp://web.stanford.edu/~mgens/ calendar_today22-03-2016 16:52:04

548 Tweet

449 Followers

171 Following

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

Medicine is the perfect proving ground for developing AI/ML for causal inference (like estimating treatment effect from non-randomized observational data). Because can validate against our randomized trials, that other fields really don't have. Will see lots of progress ~soon.

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

For anyone interested in stats/ML in oncology, please check out the 8th annual Stat4Onc symposium, happening at Stanford in May. I'll be speaking in the precision medicine session. stat4onc.org/events/stat4on…

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

A great blog post from Jessica Hullman on why "dumb" statistical models tend to outperform doctors in diagnostic tasks and how much it matters. The references are very cool too. statmodeling.stat.columbia.edu/2025/04/18/dum…

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

The billing system is an opaque mess. It's super stressful for patients too. A patient told me this week they were in an imaging trial at an unnamed center (no standard of care procedures, just research) and were accidentally billed $50K. Now they are hesitant about research :(

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

OpenEvidence (OpenEvidence) is really impressive. Kind of like UpToDate but if it just printed out the answer. Quality is high too. I love UpToDate but this feels a bit like Google with its magic algorithm going up against Yahoo with its human-curated links list in the late 90s.

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

Well this took a bit longer than expected, but I think it's finally ready! Tweet thread coming soon. Kind of anxious but hoping that some people will find it useful.

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

Congrats, we really needed a win for this patient population (mainly oral cavity pts) with high recurrence rates after standard treatment. 8% OS benefit at 2yr for CPS >= 10 group (with a CI that doesn't cross 1) adds to the strong EFS results.

Michael Gensheimer (@mfgensheimer) 's Twitter Profile Photo

For a reminder of why causal inference with retrospective data is tricky, check out Jon Mellon's paper on instrumental variable analysis. Featuring this beautiful and horrifying DAG showing how papers often oversimplify causal relationships. onlinelibrary.wiley.com/doi/10.1111/aj…

For a reminder of why causal inference with retrospective data is tricky, check out <a href="/jon_mellon/">Jon Mellon</a>'s paper on instrumental variable analysis. Featuring this beautiful and horrifying DAG showing how papers often oversimplify causal relationships. onlinelibrary.wiley.com/doi/10.1111/aj…
zack chiang (@z_chiang) 's Twitter Profile Photo

The peer-reviewed version of expansion in situ genome sequencing is now out in Science! The news is bittersweet – when we first revealed this last September, I never guessed it would be my final paper in academia, but a lot has changed. A few parting thoughts:

The peer-reviewed version of expansion in situ genome sequencing is now out in Science!

The news is bittersweet – when we first revealed this last September, I never guessed it would be my final paper in academia, but a lot has changed. A few parting thoughts: